External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy
Head & Neck · 2026
DOI: 10.1002/hed.70315 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Head & Neck, 2026. Verfasst von Gabriel Adrian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden. Hauptthemen laut MEDLINE: Tumor Burden, Chemoradiotherapy, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fru Berta Kamprads Stiftelse, Svenska Sällskapet för Medicinsk Forskning, Tegger Foundation.
Abstract (Originalsprache)
Background
Primary tumor volume (GTVp) is a key prognostic factor in oropharyngeal squamous cell carcinoma (OPSCC) treated with radiotherapy. We aimed to externally validate this association and assess its relevance in other head and neck sites.
Methods
Patients from the RADCURE dataset were analyzed using Cox regression for local failure, progression‐free survival (PFS), and overall survival (OS). Subgroup analyses included HPV status, chemotherapy use, and separate evaluations for hypopharyngeal and laryngeal cancers. Model performance was assessed using the concordance index (C‐index).
Results
Among 1286 OPSCC patients, increasing GTVp was associated with a higher risk of local failure and reduced PFS and OS, consistent across HPV and chemotherapy subgroups. Similar associations were observed in hypopharyngeal ( n = 157) and laryngeal ( n = 803) cancers. Model performance was strong (C‐index up to 0.82).
Conclusion
Primary tumor volume is a robust prognostic factor across head and neck cancer sites, supporting risk stratification in curative radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
- Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia.
- Department of Clinical Sciences Lund, Division of Oncology, Lund University, Lund, Sweden.
ORCID-Profile: Gabriel Adrian
Förderung
- Fru Berta Kamprads Stiftelse
- Svenska Sällskapet för Medicinsk Forskning
- Tegger Foundation
Zitieren
APA
Adrian, G., Änghede, A. H., McDowell, L., & Gebre-Medhin, M. (2026). External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy. Head & Neck. https://doi.org/10.1002/hed.70315
Vancouver
Adrian G, Änghede AH, McDowell L, Gebre-Medhin M. External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy. Head & Neck. 2026. doi:10.1002/hed.70315
BibTeX
@article{Adrian2026,
author = {Adrian, Gabriel and Änghede, Andre Haraldsson and McDowell, Lachlan and Gebre-Medhin, Maria},
title = {External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70315}
}
EUVIMED